Bøger i Drug Discovery Series serien

The book provides a comprehensive view of the impact and promise of phage display in drug discovery and biotechnology. Building on the success of its previous edition, the book discusses current theories, principles, and methods in the field and demonstrates applications for peptide phage display, protein phage display, and the development of novel antibodies. Also covered are applications of phage display for protein characterization and drug discovery. The book provides readers with an overview of the amazing breadth of the impact that phage display technology has had on the study of proteins in general as well as the development of proteins.

Compiles useful normalization methods developed for interpreting microarray data. This book examines the mathematical processes that are important in normalizing data and avoiding inherent systematic biases. They also review modern software, including discussions on key algorithms, comparative data, and download locations.

Explores the tools and skills required at each step of the discovery process when using biochips to determine biological outcomes. This work provides a review of the clinical and pharmacogenomic relevance of biochips, ChIP-chip assays, and high-throughput approaches.

Describes the tools available for performing various assay techniques. This book presents descriptions of methods, laboratory guidelines and protocols used to perform such methods, specific examples of each assay system and troubleshooting tools. It describes biochemical assay classes and non-class specific assay development for cell-based assays.

From basic pre-screening target selection to genetic modeling and valuable data integration, this book examines experimental methods, modeling and computational techniques used to accelerate the drug target discovery process and assess the functionality of potential targets more effectively.

The pharmaceutical industry suffers from an innovation deficit, with clinical attrition and safety-related market-withdrawal. This book scrutinizes this problem in detail, contrasting the promise of technology and industrialization with the apparent inability of industry to fully realize the tools that are available.

The pharmaceutical industry suffers from an innovation deficit, with clinical attrition and safety-related market-withdrawal rates at the same level as twenty years ago. This book scrutinizes this problem in detail, contrasting the promise of technology and industrialization with the apparent inability of industry to fully realize the tools that ar